← Back to patent-cliff list
Varenicline Tartrate Nasal Spray(Oyster/Corxel )
Tier C — Watch / tradeVarenicline Tartrate Nasal Spray(Oyster/Corxel )
Oyster Point Pharma Inc
Originator
2021
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Nicotinic acetylcholine receptor alpha-4/beta-2
Brand：Tyrvaya
Indications (approved)：Dry eye disease
Regional status
US
Approved
2021-10-15
EU
-
China
Approved
2024-11-22
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Varenicline Tartrate Nasal Spray(Oyster/Corxel )?
Approved indications include: Dry eye disease.
When does the Varenicline Tartrate Nasal Spray(Oyster/Corxel ) patent expire?
No public expiry year is available for Varenicline Tartrate Nasal Spray(Oyster/Corxel ) yet; this page updates once verified.
How do I get a quote for Varenicline Tartrate Nasal Spray(Oyster/Corxel ) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27